Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $12.92 million for the quarter.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The business had revenue of $12.25 million for the quarter, compared to analysts' expectations of $11.95 million. On average, analysts expect Entrada Therapeutics to post $1 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Entrada Therapeutics Price Performance
Shares of TRDA stock traded up $0.35 during trading hours on Friday, reaching $10.77. The stock had a trading volume of 81,583 shares, compared to its average volume of 113,265. The firm has a 50-day simple moving average of $13.51 and a 200-day simple moving average of $16.03. The firm has a market capitalization of $404.90 million, a PE ratio of 6.77 and a beta of -0.14. Entrada Therapeutics has a twelve month low of $10.26 and a twelve month high of $21.79.
Analysts Set New Price Targets
TRDA has been the topic of a number of research analyst reports. Roth Capital raised shares of Entrada Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th. Roth Mkm initiated coverage on shares of Entrada Therapeutics in a research report on Thursday, December 5th. They set a "buy" rating and a $29.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Entrada Therapeutics in a research report on Tuesday, February 25th.
Read Our Latest Analysis on Entrada Therapeutics
Insiders Place Their Bets
In other Entrada Therapeutics news, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total value of $476,359.95. Following the completion of the sale, the insider now directly owns 4,402,849 shares of the company's stock, valued at $91,447,173.73. The trade was a 0.52 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.59% of the company's stock.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Recommended Stories
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
